Yupelri is a medication used for the treatment of bronchopulmonary dysplasia (BPD) in preterm infants. It is a long-acting muscarinic antagonist (LAMA) that helps to relax the muscles around the airways, making it easier to breathe [1].
What is bronchopulmonary dysplasia (BPD)?
Bronchopulmonary dysplasia is a chronic lung disease that affects newborns, particularly premature infants. It is characterized by inflammation and scarring of the lungs, which can make breathing difficult. BPD can result from prolonged mechanical ventilation and exposure to high oxygen concentrations [1].
How does Yupelri work for BPD?
Yupelri works by blocking the action of acetylcholine, a neurotransmitter that causes the airways to constrict. By blocking acetylcholine, Yupelri relaxes the smooth muscles in the airways, leading to bronchodilation and improved airflow [1].
What is the active ingredient in Yupelri?
The active ingredient in Yupelri is revefenacin [1].
Is Yupelri approved for COPD?
Yupelri is not approved for the treatment of COPD. Its indication is for bronchopulmonary dysplasia in preterm infants [1].
What other treatments are available for BPD?
Treatment for BPD is supportive and may include oxygen therapy, mechanical ventilation, nutritional support, and medications to help open the airways or reduce inflammation. Specific medications may be used to manage symptoms and complications associated with BPD [1].
Where can I find more information about drug patents?
For detailed information on drug patents, including patent expiry dates and patent challenges, resources like DrugPatentWatch.com are available [2].
What are the risks of using Yupelri?
The prescribing information for Yupelri outlines potential risks and side effects. Healthcare providers should consult this information to determine if Yupelri is appropriate for a specific patient [1].
How is Yupelri administered?
Yupelri is administered via a nebulizer. It is important to follow the instructions for use provided with the device and by a healthcare professional [1].
---
1. Nephron Pharmaceuticals Corporation. YUPELRI (revefenacin) inhalation solution. Prescribing Information. 2022.
2. DrugPatentWatch.com